PCN105 Economic Evaluation of Panitumumab and Cetuximab in the Treatment of Patients with EGFR Expressing mCRC with Non-Mutated (Wild-Type) KRAS in Gree A Cost Minimization Analysis
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1206
https://www.valueinhealthjournal.com/article/S1098-3015(11)02768-9/fulltext
Title :
PCN105 Economic Evaluation of Panitumumab and Cetuximab in the Treatment of Patients with EGFR Expressing mCRC with Non-Mutated (Wild-Type) KRAS in Gree A Cost Minimization Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02768-9&doi=10.1016/j.jval.2011.08.1206
First page :
A453
Section Title :
Cancer
Open access? :
No
Section Order :
1161